Dogwood Therapeutics Inc is a development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy. The pipeline is focused on treating chronic neuropathic pain and neuropathy. The Company operates in one segment and is a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer.
Last trade$1.18
Day change+$0.12 (+11.32%)
Day range$1.07 – $1.19
Volume81,103
Market cap$41M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$40.52M
Price / earnings
—
Price / book
0.63×
Price / sales
405.22×
EV / sales
355.73×
EV / EBITDA
-1.91×
Profitability
Earnings per share
-$0.66
Return on assets
-33.3%
Return on equity
-39.26%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
2.78×
Quick ratio
2.78×
Cash ratio
2.28×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$16.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for DWTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$100K
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$88.1K
$0
$0
$0
$0
$0
$0
$0
Gross profit
$11.9K
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.58M
$1.63M
$2.41M
$1.47M
$1.29M
$1.35M
$1.99M
$5.23M
Research and development
$3.35M
$3.25M
$2.67M
$2.34M
$14.52M
$2.57M
$2.44M
$2.32M
Total operating expenses
$4.93M
$14.06M
$5.08M
$3.81M
$15.81M
$3.92M
$4.43M
$7.54M
Operating income
-$4.92M
-$14.06M
-$5.08M
-$3.81M
-$15.81M
-$3.92M
-$4.43M
-$7.54M
Interest expense
$42.04K
$66.35K
$0
$0
$80.58K
$111.38K
$0
$0
Income before taxes
-$4.88M
-$14.01M
-$4.99M
-$3.75M
-$15.75M
-$3.81M
-$10.73M
-$7.73M
Income taxes
-$839
-$2.48M
$1.19K
$31.84K
-$1.44K
$149
$190.54K
-$503
Net income
-$4.88M
-$11.53M
-$4.99M
-$3.78M
-$15.74M
-$3.81M
-$10.92M
-$7.73M
Net income attributable to common shareholders
-$4.88M
-$11.53M
-$4.99M
-$3.78M
-$15.74M
-$3.81M
-$12.18M
-$8.24M
EBITDA
-$4.92M
-$4.87M
-$5.08M
-$3.81M
-$15.84M
-$3.91M
-$4.41M
-$7.53M
Basic earnings per share
-$0.14
-$0.34
-$0.15
-$0.26
-$8.20
-$1.99
-$8.45
-$6.27
Diluted earnings per share
-$0.14
-$0.34
-$0.15
-$0.26
-$8.20
-$1.99
-$8.45
-$6.27
Recent news
Company coverage with links to the original publishers.
DelveInsight released a comprehensive analysis of the chronic and acute pain clinical trial pipeline, identifying 150+ active companies developing 200+ pipeline drugs across various clinical stages. The report highlights a shift toward non-opioid, targeted, and multimodal approaches due to growing concerns about opioid dependence. Recent developments include FDA orphan drug designation for Adolore BioTherapeutics' gene therapy, positive Phase IIb results for Dogwood Therapeutics' Halneuron, and Phase III publication of Vertanical's VER-01 for chronic low back pain.
The chemotherapy-induced peripheral neuropathy (CIPN) treatment market is expected to grow significantly between 2025-2034, driven by rising cancer incidence, lack of approved therapies, and emerging novel drug treatments.
Dogwood Therapeutics reported ongoing Phase 2b trial for Halneuron®, a potential treatment for chemotherapy-induced neuropathic pain, with 52 patients enrolled and interim data expected in Q4 2025. The company experienced increased research and development expenses and reported a net loss of $3.8 million for Q2 2025.
The sodium channel blocker market is expanding due to the increasing prevalence of neuropathic pain and the rising incidence of cardiac arrhythmias. Over 20 pharmaceutical companies are actively developing 25+ pipeline sodium channel blockers, with promising drugs like Cenobamate, VX-548, and Vormatrigine in different clinical trial phases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.